Effective treatment of idiopathic chronic cold urticaria with omalizumab: Report of 3 cases

Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

“…At month 6, eight of 10 patients who continued omalizumab therapy had a complete response, with the two others having a partial response. On the other hand, the French study evaluated three patients with refractory chronic cold urticaria (CCU) and found the optimal dose and dosing interval to be a starting cycle of four subcutaneous injections of omalizumab 300 mg every 2 weeks, with subsequent injections given depending on the progression of the symptoms . The three patients studied all displayed remission of symptoms; however, in two of them, disease‐related symptoms reappeared during a period of treatment interruption, suggesting that shorter therapy cycles should be restarted in both patients, which rapidly resulted in normalization of the symptoms.…”

“…Further evidence of omalizumab efficacy was seen in two studies, the first in Spain 17 and the second in France, 18 both published in 2013. The Spanish study evaluated the effectiveness of omalizumab in 15 patients with CIU, 12 of whom responded within the first 3 months of treatment (three with complete response and nine with partial response).…”

Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort

“…3,11,16 In contrast to cyclosporine, omalizumab was found to be an effective therapeutic alternative for patients with refractory ACU. 4,17,18 Importantly, the presence of other family members with similar symptoms should always be ruled out in patients with ACU, because specific treatments (eg, antieinterleukin-1) have demonstrated effectiveness in the management of familial cold-induced urticaria syndromes. [19][20][21] Moreover, regardless of the prescribed treatment, self-limited evolution can be seen in some patients with ACU.…”

Comparable actions of omalizumab on mast cells and basophils

“…It was also recently proposed that IgE plays a role in the amplification of inflammation favouring the infiltration of immune cells into secondary lymphoid organs [25,26]. Moreover, OmAb has been reported to control physical urticarias [32][33][34]. In the case of chronic urticaria, the exact mechanism of OmAb is still unknown.…”

“…In the case of chronic urticaria, the exact mechanism of OmAb is still unknown. Moreover, OmAb has been reported to control physical urticarias [32][33][34]. Thus, OmAb could have additional properties that act directly on mast cells and basophils.…”